Long-Term Ocrelizumab Benefits Seen in PPMS

(MedPage Today) -- Early, continuous treatment with ocrelizumab (Ocrevus) led to sustained slowing of disease progression in primary progressive multiple sclerosis (PPMS), long-term data from the ORATORIO extension study suggested.
Most measures...